Beam Therapeutics (BEAM) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Beam Therapeutics (BEAM) is Neutral.

The composite score behind that read is -0.03, weighing +0.23 of bullish evidence against -0.26 bearish.

Beam Therapeutics last closed at $25.70, +4.47% on the session.

Against the IVW growth benchmark the position is +3.67% over the forecast window.

The read is built from 15 underlying insights — 4 bullish and 11 bearish.

Agreement across those insights is 73%.

11 graded predictions for BEAM so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Beam Therapeutics in the 33rd percentile on return on equity, where 100 is best.

Beam Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $2.54B.

StockMap tracks Beam Therapeutics as the 75th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Beam Therapeutics ranks 125th of 381 in the group, against a group median of -0.08.